Skip to main content

The BioPharma Dive Outlook on 2023

2022 brought significant political defeat for the drug industry with the passage of price reforms, as well as renewed scrutiny on the FDA. The months ahead in 2023 are expected to bring FDA decisions on a number of closely tracked drugs, anticipated clinical trial readouts, and much more.

included in this trendline
  • The biggest questions facing the pharma industry
  • 5 consequential FDA decisions to watch
  • The top 10 clinical trials to keep an eye on
Note: Trendlines are a premium product, available to subscribers of our free newsletters. Access this Trendline by signing up for the BioPharma Dive newsletter or enter your information if you're already subscribed.
Produced by our team of award-winning journalists, the BioPharma Dive Outlook for 2023 can help you navigate the road ahead in the pharma industry.
Davide Savenije Editor-in-Chief at Industry Dive.